Unsurprisingly, Corren et al.58 reported that anti-TSLP monoclonal antibody reduces annual exacerbation rates by 62%–71% at different doses in uncontrolled asthma despite treatment with long-acting β2 agonists and medium-to-high doses of ICS. Here, TSLP is linked to asthma.